When hypoxia signalling meets the ubiquitin-proteasomal pathway, new targets for cancer therapy
- 28 February 2005
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 53 (2) , 115-123
- https://doi.org/10.1016/j.critrevonc.2004.09.003
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Targeting HIF-1 for cancer therapyNature Reviews Cancer, 2003
- Therapeutic anti-cancer targets upstream of the proteasomeCancer Treatment Reviews, 2003
- SUMO-1 conjugation to intact DNA topoisomerase I amplifies cleavable complex formation induced by camptothecinOncogene, 2002
- The Aryl Hydrocarbon Receptor Nuclear Transporter Is Modulated by the SUMO-1 Conjugation SystemJournal of Biological Chemistry, 2002
- Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel–Lindau tumor suppressorBiochemical and Biophysical Research Communications, 2002
- Deadly encounter: ubiquitin meets apoptosisNature Reviews Molecular Cell Biology, 2002
- Nucleolar Delocalization of Human Topoisomerase I in Response to Topotecan Correlates with Sumoylation of the ProteinJournal of Biological Chemistry, 2002
- Hypoxia: the tumor's gateway to progression along the angiogenic pathwayTrends in Cell Biology, 2001
- Hypoxia-inducible Factor-2α (HIF-2α) Is Involved in the Apoptotic Response to Hypoglycemia but Not to HypoxiaJournal of Biological Chemistry, 2001
- Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profilingOncogene, 2000